CDK4/6 inhibitor protects against myocardial cells apoptosis by inhibiting RB phosphorylation in H9c2 cells

Area of Science:

• Cardiovascular Biology
• Cancer Biology
• Cellular Mechanisms

Background:

• Cell cycle dysregulation is a hallmark of human cancers.
• CDK4/6 inhibitors are investigated for cancer therapy and may possess cardioprotective effects.
• High glucose (HG) can induce apoptosis in H9c2 cells, a model for cardiomyocytes.

Purpose of the Study:

• To investigate the regulatory effect of Palbociclib on high glucose-induced apoptosis in H9c2 cells.
• To elucidate the underlying molecular mechanisms of Palbociclib's action.

Main Methods:

• H9c2 cells were treated with high glucose and Palbociclib.
• Assessed intracellular reactive oxygen species (ROS) production.
• Measured mitochondrial membrane potential.
• Evaluated apoptosis markers (Bcl-2/Bax ratio, cleaved-caspase-3).
• Analyzed RB phosphorylation and p53 expression.

Main Results:

• Palbociclib reduced intracellular ROS production in HG-treated H9c2 cells.
• Palbociclib augmented mitochondrial membrane potential.
• Palbociclib inhibited apoptosis, evidenced by an increased Bcl-2/Bax ratio and decreased cleaved-caspase-3.
• Palbociclib affected RB phosphorylation and p53 expression.

Conclusions:

• Palbociclib exhibits anti-apoptotic effects on H9c2 cells exposed to high glucose.
• The protective mechanism involves the modulation of the mitochondrial apoptotic pathway.
• Palbociclib's efficacy may be linked to its impact on ROS, mitochondrial integrity, and key apoptosis-related proteins.